Investor Relations
Clinical Cell Culture Limited has evolved from its early start-up days as a private skin culture facility to a public listed biomedical company and world leader in autologous tissue engineered cellular technology. C3 is committed to increasing share holder value by developing innovative products with real market needs and introducing them into the global marketplace.
It is a privilege to lead this innovative biomedical company forward in pursuit of a noble vision: to make a difference in the lives of the many people who can benefit from skin regeneration. I, along with my fellow Directors and our team of dedicated employees at C3, look forward to fulfilling this vision and exceeding the expectations of our shareholders.
Dalton Gooding
